+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Encephalitis Treatment Market by Treatment Type, Disease Type, Route of Administration, Patient Demographics, End-User, Drug Class, Mode of Purchase - Global Forecast 2025-2030- Product Image
Encephalitis Treatment Market by Treatment Type, Disease Type, Route of Administration, Patient Demographics, End-User, Drug Class, Mode of Purchase - Global Forecast 2025-2030- Product Image
Sale

Encephalitis Treatment Market by Treatment Type, Disease Type, Route of Administration, Patient Demographics, End-User, Drug Class, Mode of Purchase - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 195 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6015275
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Encephalitis Treatment Market grew from USD 14.32 billion in 2023 to USD 15.49 billion in 2024. It is expected to continue growing at a CAGR of 6.59%, reaching USD 22.39 billion by 2030.

The Encephalitis Treatment market encompasses a range of pharmaceuticals and therapies designed to manage and alleviate the symptoms of encephalitis, an inflammation of the brain often caused by infection or autoimmune responses. The necessity for effective encephalitis treatments is driven by the severity of the condition, which can lead to serious neurological implications if not promptly and properly treated. These treatments are applied across hospitals, specialized clinics, and in-home care settings, catering to both acute and long-term management of the condition. Within this context, the end-use scope extends beyond individual patients to include healthcare systems and insurers who aim to mitigate long-term care costs and improve patient outcomes.

Key growth factors in the market include advancements in diagnostic tools, increasing awareness about neurological disorders, and the rising prevalence of encephalitis-linked viruses such as herpes simplex and various arboviruses. Opportunities lie in developing targeted antiviral and immunomodulating therapies, driven by ongoing research in virology and immunology. The growing use of AI in diagnostics and personalized medicine also presents significant potential, enabling more precise and efficient treatment plans. Market recommendations focus on investment in R&D for innovative drugs and biologics, establishing strategic partnerships with research institutes, and enhancing access through competitive pricing strategies.

Challenges include the high cost of treatment development, stringent regulatory requirements, and the complex nature of encephalitis pathogenesis, which can hinder quick advancement in therapies. Additionally, the market may face hurdles in the form of limited patient population size for certain types of encephalitis, impacting the commercial viability of new treatments. Innovations should prioritize developing drugs with broad-spectrum efficacy and addressing diagnostic accuracy issues, while research should focus on understanding genetic and environmental risk factors to better tailor treatment protocols. The nature of the encephalitis treatment market is dynamic, requiring agile adaptation to technological advancements and regulatory landscapes to sustain growth and patient care efficacy.

Understanding Market Dynamics in the Encephalitis Treatment Market

The Encephalitis Treatment Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Growing prevalence of encephalitis conditions globally increases demand for effective treatment options
    • Expansion of healthcare infrastructure and services enhances access to encephalitis diagnosis and therapies
    • Advancements in medical research contribute to the development of innovative encephalitis treatment solutions
    • Increasing awareness about encephalitis symptoms and treatment boosts early diagnosis and therapeutic interventions
  • Market Restraints
    • High cost of treatment
  • Market Opportunities
    • Growing demand for advanced diagnostic tools for early detection and management of encephalitis
    • Collaborations between pharmaceutical companies and academic institutions for innovative encephalitis therapies
    • Increasing investment in research and development for novel encephalitis treatment solutions
  • Market Challenges
    • Complexity in diagnosis and differentiation

Exploring Porter’s Five Forces for the Encephalitis Treatment Market

Porter’s Five Forces framework further strengthens the insights of the Encephalitis Treatment Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Encephalitis Treatment Market

External macro-environmental factors deeply influence the performance of the Encephalitis Treatment Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Encephalitis Treatment Market

The Encephalitis Treatment Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Encephalitis Treatment Market

The Encephalitis Treatment Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Encephalitis Treatment Market

The Encephalitis Treatment Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Encephalitis Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allergan plc, Amgen Inc., AstraZeneca plc, Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, CSL Limited, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and UCB S.A..

Market Segmentation & Coverage

This research report categorizes the Encephalitis Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Treatment Type
    • Antiviral Medication
    • Corticosteroids
    • Immunotherapy
    • Supportive Care
  • Disease Type
    • Autoimmune Encephalitis
      • Anti-NMDA Receptor Encephalitis
      • Hashimoto's Encephalopathy
      • Limbic Encephalitis
    • Infectious Encephalitis
      • Bacterial Encephalitis
      • Fungal Encephalitis
      • Parasitic Encephalitis
      • Viral Encephalitis
  • Route of Administration
    • Intramuscular
    • Intravenous
    • Oral
  • Patient Demographics
    • Adult
    • Geriatric
    • Pediatric
  • End-User
    • Clinics
    • Homecare Settings
    • Hospitals
    • Research Institutes
  • Drug Class
    • Antivirals
      • Acyclovir
      • Foscarnet
      • Ganciclovir
    • Corticosteroids
      • Dexamethasone
      • Prednisone
    • Immunoglobulins
      • IVIG
  • Mode of Purchase
    • Over-The-Counter
    • Prescription
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing prevalence of encephalitis conditions globally increases demand for effective treatment options
5.1.1.2. Expansion of healthcare infrastructure and services enhances access to encephalitis diagnosis and therapies
5.1.1.3. Advancements in medical research contribute to the development of innovative encephalitis treatment solutions
5.1.1.4. Increasing awareness about encephalitis symptoms and treatment boosts early diagnosis and therapeutic interventions
5.1.2. Restraints
5.1.2.1. High cost of treatment
5.1.3. Opportunities
5.1.3.1. Growing demand for advanced diagnostic tools for early detection and management of encephalitis
5.1.3.2. Collaborations between pharmaceutical companies and academic institutions for innovative encephalitis therapies
5.1.3.3. Increasing investment in research and development for novel encephalitis treatment solutions
5.1.4. Challenges
5.1.4.1. Complexity in diagnosis and differentiation
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental

6. Encephalitis Treatment Market, by Treatment Type
6.1. Introduction
6.2. Antiviral Medication
6.3. Corticosteroids
6.4. Immunotherapy
6.5. Supportive Care

7. Encephalitis Treatment Market, by Disease Type
7.1. Introduction
7.2. Autoimmune Encephalitis
7.2.1. Anti-NMDA Receptor Encephalitis
7.2.2. Hashimoto's Encephalopathy
7.2.3. Limbic Encephalitis
7.3. Infectious Encephalitis
7.3.1. Bacterial Encephalitis
7.3.2. Fungal Encephalitis
7.3.3. Parasitic Encephalitis
7.3.4. Viral Encephalitis

8. Encephalitis Treatment Market, by Route of Administration
8.1. Introduction
8.2. Intramuscular
8.3. Intravenous
8.4. Oral

9. Encephalitis Treatment Market, by Patient Demographics
9.1. Introduction
9.2. Adult
9.3. Geriatric
9.4. Pediatric

10. Encephalitis Treatment Market, by End-User
10.1. Introduction
10.2. Clinics
10.3. Homecare Settings
10.4. Hospitals
10.5. Research Institutes

11. Encephalitis Treatment Market, by Drug Class
11.1. Introduction
11.2. Antivirals
11.2.1. Acyclovir
11.2.2. Foscarnet
11.2.3. Ganciclovir
11.3. Corticosteroids
11.3.1. Dexamethasone
11.3.2. Prednisone
11.4. Immunoglobulins
11.4.1. IVIG

12. Encephalitis Treatment Market, by Mode of Purchase
12.1. Introduction
12.2. Over-The-Counter
12.3. Prescription

13. Americas Encephalitis Treatment Market
13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States

14. Asia-Pacific Encephalitis Treatment Market
14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam

15. Europe, Middle East & Africa Encephalitis Treatment Market
15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom

16. Competitive Landscape
16.1. Market Share Analysis, 2023
16.2. FPNV Positioning Matrix, 2023
16.3. Competitive Scenario Analysis
16.4. Strategy Analysis & Recommendation


List of Figures
FIGURE 1. ENCEPHALITIS TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. ENCEPHALITIS TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2030 (%)
FIGURE 13. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 15. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 17. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2023 VS 2030 (%)
FIGURE 19. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 23. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 25. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 28. ENCEPHALITIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 29. ENCEPHALITIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023


List of Tables
TABLE 1. ENCEPHALITIS TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ENCEPHALITIS TREATMENT MARKET DYNAMICS
TABLE 7. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTI-NMDA RECEPTOR ENCEPHALITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY HASHIMOTO'S ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY LIMBIC ENCEPHALITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY BACTERIAL ENCEPHALITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY FUNGAL ENCEPHALITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY PARASITIC ENCEPHALITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY VIRAL ENCEPHALITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ACYCLOVIR, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY FOSCARNET, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY GANCICLOVIR, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY PREDNISONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY IVIG, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 90. CANADA ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 91. CANADA ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 92. CANADA ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 93. CANADA ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 94. CANADA ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 95. CANADA ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 96. CANADA ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 97. CANADA ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 98. CANADA ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 99. CANADA ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 100. CANADA ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 101. CANADA ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 102. MEXICO ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 103. MEXICO ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 104. MEXICO ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 105. MEXICO ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 106. MEXICO ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 107. MEXICO ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 108. MEXICO ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 109. MEXICO ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 110. MEXICO ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 111. MEXICO ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 112. MEXICO ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 113. MEXICO ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 114. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 115. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 116. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 117. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 118. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 121. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 122. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 123. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 124. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 125. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 126. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 127. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 128. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 129. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 130. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 131. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 132. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 133. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 134. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 135. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 136. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 137. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 138. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 139. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 140. AUSTRALIA ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 141. AUSTRALIA ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 142. AUSTRALIA ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 143. AUSTRALIA ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 144. AUSTRALIA ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. AUSTRALIA ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 146. AUSTRALIA ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 147. AUSTRALIA ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 148. AUSTRALIA ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 149. AUSTRALIA ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 150. AUSTRALIA ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 151. AUSTRALIA ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 152. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 153. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 154. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 155. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 156. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 157. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 158. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 159. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 160. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 161. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 162. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 163. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 164. INDIA ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 165. INDIA ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 166. INDIA ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 167. INDIA ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 168. INDIA ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 169. INDIA ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 170. INDIA ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 171. INDIA ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 172. INDIA ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 173. INDIA ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 174. INDIA ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 175. INDIA ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 176. INDONESIA ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 177. INDONESIA ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 178. INDONESIA ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 179. INDONESIA ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 180. INDONESIA ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 181. INDONESIA ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 182. INDONESIA ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 183. INDONESIA ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 184. INDONESIA ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 185. INDONESIA ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 186. INDONESIA ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 187. INDONESIA ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 188. JAPAN ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 189. JAPAN ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 190. JAPAN ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 191. JAPAN ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 192. JAPAN ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 193. JAPAN ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 194. JAPAN ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 195. JAPAN ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 196. JAPAN ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 197. JAPAN ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 198. JAPAN ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 199. JAPAN ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 200. MALAYSIA ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 201. MALAYSIA ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 202. MALAYSIA ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 203. MALAYSIA ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 204. MALAYSIA ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 205. MALAYSIA ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 206. MALAYSIA ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 207. MALAYSIA ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 208. MALAYSIA ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 209. MALAYSIA ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 210. MALAYSIA ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 211. MALAYSIA ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 212. PHILIPPINES ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 213. PHILIPPINES ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 214. PHILIPPINES ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 215. PHILIPPINES ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 216. PHILIPPINES ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 217. PHILIPPINES ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 218. PHILIPPINES ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 219. PHILIPPINES ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 220. PHILIPPINES ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 221. PHILIPPINES ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 222. PHILIPPINES ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 223. PHILIPPINES ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 224. SINGAPORE ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 225. SINGAPORE ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 226. SINGAPORE ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 227. SINGAPORE ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 228. SINGAPORE ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 229. SINGAPORE ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 230. SINGAPORE ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 231. SINGAPORE ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 232. SINGAPORE ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 233. SINGAPORE ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 234. SINGAPORE ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 235. SINGAPORE ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 236. SOUTH KOREA ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 237. SOUTH KOREA ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 238. SOUTH KOREA ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 239. SOUTH KOREA ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 240. SOUTH KOREA ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 241. SOUTH KOREA ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 242. SOUTH KOREA ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 243. SOUTH KOREA ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 244. SOUTH KOREA ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 245. SOUTH KOREA ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 246. SOUTH KOREA ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 247. SOUTH KOREA ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 248. TAIWAN ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 249. TAIWAN ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 250. TAIWAN ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 251. TAIWAN ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 252. TAIWAN ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 253. TAIWAN ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 254. TAIWAN ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 255. TAIWAN ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 256. TAIWAN ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 257. TAIWAN ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 258. TAIWAN ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 259. TAIWAN ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 260. THAILAND ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 261. THAILAND ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 262. THAILAND ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 263. THAILAND ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 264. THAILAND ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 265. THAILAND ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 266. THAILAND ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 267. THAILAND ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 268. THAILAND ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 269. THAILAND ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 270. THAILAND ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 271. THAILAND ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 272. VIETNAM ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 273. VIETNAM ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 274. VIETNAM ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 275. VIETNAM ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 276. VIETNAM ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 277. VIETNAM ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 278. VIETNAM ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 279. VIETNAM ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 280. VIETNAM ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 281. VIETNAM ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 282. VIETNAM ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 283. VIETNAM ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 284. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 285. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 286. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 287. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 288. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 289. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 290. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 291. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 292. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 293. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 294. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 295. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 296. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 297. DENMARK ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 298. DENMARK ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 299. DENMARK ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 300. DENMARK ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 301. DENMARK ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 302. DENMARK ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 303. DENMARK ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 304. DENMARK ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 305. DENMARK ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 306. DENMARK ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 307. DENMARK ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 308. DENMARK ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 309. EGYPT ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 310. EGYPT ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 311. EGYPT ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 312. EGYPT ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 313. EGYPT ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 314. EGYPT ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 315. EGYPT ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 316. EGYPT ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 317. EGYPT ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 318. EGYPT ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 319. EGYPT ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 320. EGYPT ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
TABLE 321. FINLAND ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 322. FINLAND ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 323. FINLAND ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
TABLE 324. FINLAND ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENC

Companies Mentioned

The leading players in the Encephalitis Treatment Market, which are profiled in this report, include:
  • AbbVie Inc.
  • Allergan plc
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • CSL Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages195
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 15.49 Billion
Forecasted Market Value ( USD ) by 2030 $ 22.39 Billion
Compound Annual Growth Rate6.5%
Regions CoveredGlobal
No. of Companies Mentioned20

Related Topics

Related Reports

Encephalitis Treatment Global Market Report 2024 - Product Image

Encephalitis Treatment Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Autoimmune Encephalitis (AE) - Pipeline Insight, 2024 - Product Image

Autoimmune Encephalitis (AE) - Pipeline Insight, 2024

  • Drug Pipelines
  • 60 Pages
  • Global
From
Tick Borne Encephalitis - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Tick Borne Encephalitis - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Cytomegalovirus Treatment Market by Diseases, Drug, Distribution Channel, Application - Global Forecast 2025-2030 - Product Image

Cytomegalovirus Treatment Market by Diseases, Drug, Distribution Channel, Application - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Hunter's Tropical Medicine and Emerging Infectious Diseases. Edition No. 10 - Product Image

Hunter's Tropical Medicine and Emerging Infectious Diseases. Edition No. 10

  • Book

About the Encephalitis Drug Market

Encephalitis is an inflammation of the brain caused by a virus or other infectious agent. Infectious Diseases Drugs are used to treat this condition, and the Encephalitis Drug market is a subset of this larger market. These drugs are used to reduce inflammation, reduce symptoms, and prevent further damage to the brain. They may also be used to treat complications such as seizures, coma, and death. Common drugs used to treat encephalitis include antivirals, corticosteroids, and immunosuppressants. The Encephalitis Drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in this market include GlaxoSmithKline, Merck & Co., Pfizer, Sanofi, and Johnson & Johnson. Other companies include AstraZeneca, Novartis, and Bristol-Myers Squibb. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.